{
  "items": "35",
  "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
  "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
  "feed": [
    {
      "title": "Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference",
      "url": "https://www.globenewswire.com/news-release/2025/12/18/3207757/0/en/Alpha-Tau-to-Present-at-the-J-P-Morgan-2026-Healthcare-Conference.html",
      "time_published": "20251218T140856",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026. The presentation will cover recent company achievements and upcoming data milestones. They will also host institutional investor meetings, with a webcast link available on the company's investor relations website.",
      "banner_image": "https://ml.globenewswire.com/media/Y2E0ZmQ4YWUtZTYyMC00MmY4LThjZDItZTI5OWY4YzNjOWM1LTEyNjEwOTEtMjAyNS0xMi0xOC1lbg==/tiny/Alpha-Tau-Medical-Ltd-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.910728"
        },
        {
          "topic": "finance",
          "relevance_score": "0.749606"
        }
      ],
      "overall_sentiment_score": 0.256672,
      "overall_sentiment_label": "Somewhat-Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.281656",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Medical to Present Corporate Update at J.P. Morgan 2026 Healthcare Conference",
      "url": "https://www.tipranks.com/news/company-announcements/alpha-tau-medical-to-present-corporate-update-at-j-p-morgan-2026-healthcare-conference",
      "time_published": "20251218T140856",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. (DRTS) announced that its CEO and CFO will present a corporate overview and update at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026. The presentation will highlight recent achievements and upcoming data milestones for its Alpha DaRT solid-tumor therapy. While analysts currently rate DRTS as a Buy with a $7.00 price target, TipRanks\u2019 AI Analyst, Spark, advises caution due to financial challenges and lack of revenue, rating it as Underperform.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1911898180-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.902985"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.836298"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.710845"
        }
      ],
      "overall_sentiment_score": 0.01567,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "0.325927",
          "ticker_sentiment_score": "0.048414",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "FDA gives nod to trial of alpha-radiation therapy for prostate cancer",
      "url": "https://www.urologytimes.com/view/fda-gives-nod-to-trial-of-alpha-radiation-therapy-for-prostate-cancer",
      "time_published": "20251211T190906",
      "authors": [
        "Hannah Clarke"
      ],
      "summary": "Alpha Tau Medical has received FDA approval to initiate a pilot study using Alpha DaRT, an alpha-radiation therapy, for patients with locally recurrent prostate cancer. The therapy uses radium-224 to target tumors intratumorally, aiming to preserve surrounding healthy tissue. The trial will enroll up to 12 patients in the US, focusing on safety as the primary endpoint.",
      "banner_image": "https://cdn.sanity.io/images/0vv8moc6/urologytimes/86bcab9098ec30ecd3656ad2e98a4323941a53d9-1200x800.jpg?w=350&fit=crop&auto=format",
      "source": "Urology Times",
      "category_within_source": "General",
      "source_domain": "Urology Times",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949063"
        }
      ],
      "overall_sentiment_score": 0.88751,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.872702",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "What's Next For Alpha Tau: Major Milestones Expected Through Early 2026",
      "url": "https://www.rttnews.com/amp/3602935/what-s-next-for-alpha-tau-major-milestones-expected-through-early-2026.aspx",
      "time_published": "20251211T080931",
      "authors": [
        "RTTNews Staff Writer"
      ],
      "summary": "Alpha Tau Medical (DRTS) recently saw a significant stock surge following its progress in clinical programs, manufacturing expansion, and upcoming regulatory milestones for its Alpha DaRT radiation therapy. The company is advancing studies for recurrent glioblastoma multiforme, pancreatic cancer, and recurrent prostate cancer, with key clinical and regulatory readouts anticipated through early 2026. This period of intense activity and a strengthened cash position underscore the company's efforts to bring its targeted cancer therapy to market for difficult-to-treat cancers.",
      "banner_image": "NULL",
      "source": "RTTNews",
      "category_within_source": "General",
      "source_domain": "RTTNews",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.942652"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.728250"
        }
      ],
      "overall_sentiment_score": 0.04148,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "0.340358",
          "ticker_sentiment_score": "0.002156",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "What's Next For Alpha Tau: Major Milestones Expected Through Early 2026",
      "url": "https://www.rttnews.com/3602935/what-s-next-for-alpha-tau-major-milestones-expected-through-early-2026.aspx",
      "time_published": "20251211T025400",
      "authors": [
        "RTTNews Staff Writer"
      ],
      "summary": "Alpha Tau Medical Ltd. (DRTS) is advancing its Alpha DaRT radiation therapy platform, attracting significant investor attention with its stock recently surging to a new 52-week high. The company is progressing with several clinical programs, including studies for recurrent glioblastoma, pancreatic cancer, and recurrent prostate cancer, and expanding its manufacturing capabilities. Key milestones are anticipated through early 2026, including regulatory responses and completion of patient recruitment for pivotal trials, supported by a strong financial position with $75.9 million in cash as of September 30, 2025.",
      "banner_image": "NULL",
      "source": "RTTNews",
      "category_within_source": "General",
      "source_domain": "RTTNews",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.835850"
        }
      ],
      "overall_sentiment_score": 0.882966,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.861303",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Why Did Alpha Tau Medical (DRTS) Shares Jump Over 25% In After-Hours Trading?",
      "url": "https://www.sahmcapital.com/news/content/why-did-alpha-tau-medical-drts-shares-jump-over-25-in-after-hours-trading-2025-12-10",
      "time_published": "20251210T220912",
      "authors": [
        "Benzinga News"
      ],
      "summary": "Alpha Tau Medical (DRTS) shares surged over 25% in after-hours trading following the announcement of the first patient treatment in a pilot study for recurrent glioblastoma multiforme. The treatment utilizes the company's Alpha DaRT alpha-radiation cancer therapy, which has received FDA Breakthrough Device Designation. This marks a significant step for the company in addressing high unmet needs in cancer treatment.",
      "banner_image": "https://editorial-assets.benzinga.com/wp-content/uploads/2025/12/10011614/image-166.png",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.902448"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.720806"
        }
      ],
      "overall_sentiment_score": 0.017205,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "0.342994",
          "ticker_sentiment_score": "0.000037",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock",
      "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-alpha-tau-medical-stock-93CH-4401146",
      "time_published": "20251210T210926",
      "authors": [
        "Investing.com"
      ],
      "summary": "H.C. Wainwright has reiterated its Buy rating and $9.00 price target on Alpha Tau Medical Ltd. (NASDAQ:DRTS) following the company\u2019s announcement about its brain cancer treatment. This target represents over 112% upside from the current price. The company has also recently received a radioactive material license and completed the first phase of construction at its manufacturing facility, indicating significant progress in its operational infrastructure.",
      "banner_image": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.941478"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.806648"
        }
      ],
      "overall_sentiment_score": 0.615385,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.607796",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University",
      "url": "https://markets.businessinsider.com/news/stocks/alpha-tau-successfully-treats-first-patient-in-its-u-s-trial-for-patients-with-recurrent-glioblastoma-at-the-james-cancer-hospital-at-the-ohio-state-university-1035629369",
      "time_published": "20251210T200902",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. has successfully treated the first patient in its U.S. pilot study for recurrent glioblastoma multiforme (GBM) using its Alpha DaRT\u00ae technology at The James Cancer Hospital at The Ohio State University. This marks the first time Alpha DaRT has been used to treat brain cancer, addressing a critical unmet need for patients with this aggressive and treatment-resistant form of cancer. The study aims to evaluate the feasibility and safety of the treatment, building on promising pre-clinical results and supported by FDA's Breakthrough Device Designation.",
      "banner_image": "https://www.globenewswire.com/NewsRoom/AttachmentNg/71cc88b1-7458-45c0-8793-6d5c1cb1068f",
      "source": "markets.businessinsider.com",
      "category_within_source": "General",
      "source_domain": "markets.businessinsider.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913030"
        }
      ],
      "overall_sentiment_score": 0.857321,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.875402",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau treats first US patient with Alpha DaRT for glioblastoma",
      "url": "https://www.msn.com/en-us/money/savingandinvesting/alpha-tau-treats-first-us-patient-with-alpha-dart-for-glioblastoma/ar-AA1S1o14",
      "time_published": "20251209T220931",
      "authors": [],
      "summary": "Alpha Tau Medical has treated its first US patient with Alpha DaRT (Dose Escalated Alpha Therapy) for recurrent glioblastoma at the MD Anderson Cancer Center. This milestone is part of an ongoing pilot study assessing the safety and efficacy of the Alpha DaRT device for glioblastoma. The company recently completed fundraising and is expanding its clinical trials for various cancers.",
      "banner_image": null,
      "source": "MSN",
      "category_within_source": "General",
      "source_domain": "MSN",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.932784"
        }
      ],
      "overall_sentiment_score": 0.478661,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.489636",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Study: Alpha Tau Successfully Treats First Patient with Recurrent Glioblastoma",
      "url": "https://www.itnonline.com/content/study-alpha-tau-successfully-treats-first-patient-recurrent-glioblastoma",
      "time_published": "20251209T170852",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. has successfully treated the first patient in its pilot study for recurrent glioblastoma multiforme (GBM) using its Alpha DaRT technology. This marks the first time brain cancer has been treated with Alpha DaRT, offering a new local therapy option for GBM patients who face a devastating prognosis. The treatment was performed at The Ohio State University Center, utilizing a novel delivery approach for intracranial use.",
      "banner_image": "https://www.itnonline.com/sites/default/files/styles/content_large/public/Alpha%20Tau%20alpha-dart-glioblastoma-patient.png?itok=Xj3tQUCB",
      "source": "Imaging Technology News",
      "category_within_source": "General",
      "source_domain": "Imaging Technology News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.944886"
        }
      ],
      "overall_sentiment_score": 0.593019,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.866927",
          "ticker_sentiment_label": "Bullish"
        },
        {
          "ticker": "GEHC",
          "relevance_score": "0.638312",
          "ticker_sentiment_score": "0.288593",
          "ticker_sentiment_label": "Somewhat-Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Medical Ltd. Successfully Treats First Patient in Its U.S. Trial for Patients with Recurrent Glioblastoma At the James Cancer Hospital At the Ohio State University",
      "url": "https://www.marketscreener.com/news/alpha-tau-medical-ltd-successfully-treats-first-patient-in-its-u-s-trial-for-patients-with-recurre-ce7d51d2d080f625",
      "time_published": "20251209T160852",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. announced the successful treatment of the first patient in its U.S. pilot study for recurrent glioblastoma multiforme (GBM) using the Alpha DaRT technology. The treatment, performed at The Ohio State University Center, utilized a novel intracranial delivery approach ensuring over 95% tumor coverage. The trial aims to assess the feasibility and safety of Alpha DaRT in up to ten U.S. patients with recurrent glioblastoma not suitable for surgical resection.",
      "banner_image": "NULL",
      "source": "marketscreener.com",
      "category_within_source": "General",
      "source_domain": "marketscreener.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.919709"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.732273"
        }
      ],
      "overall_sentiment_score": 0.400358,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.428868",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Treats First U.S. Patient with Alpha DaRT for Glioblastoma",
      "url": "https://www.tipranks.com/news/company-announcements/alpha-tau-treats-first-u-s-patient-with-alpha-dart-for-glioblastoma",
      "time_published": "20251209T140852",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. announced the successful treatment of the first U.S. patient for recurrent glioblastoma using its Alpha DaRT technology. This pilot study, conducted at The Ohio State University, is part of Alpha Tau\u2019s strategy to address unmet needs in cancer treatment and has received FDA\u2019s Breakthrough Device Designation. Despite the clinical milestone, TipRanks\u2019 AI Analyst, Spark, rates DRTS as Underperform due to financial challenges and low profitability.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1279492897-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.938434"
        }
      ],
      "overall_sentiment_score": 0.116459,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.130099",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alpha Tau (Nasdaq: DRTS) gives first Alpha DaRT brain treatment in OSU GBM study",
      "url": "https://www.stocktitan.net/news/DRTS/alpha-tau-successfully-treats-first-patient-in-its-u-s-trial-for-1q6qtdyblnjk.html",
      "time_published": "20251209T140852",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau (Nasdaq: DRTS) has successfully treated the first patient in its U.S. pilot study for recurrent glioblastoma multiforme (GBM) using the Alpha DaRT technology at The Ohio State University. This marks a significant milestone, being the first-ever brain cancer treatment with Alpha DaRT, which achieved over 95% tumor-volume coverage and integrates with standard brain navigation systems. The company holds FDA Breakthrough Device Designation for this technology, underscoring its potential in treating a highly aggressive cancer with a poor prognosis.",
      "banner_image": "https://www.globenewswire.com/NewsRoom/AttachmentNg/71cc88b1-7458-45c0-8793-6d5c1cb1068f",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.909270"
        }
      ],
      "overall_sentiment_score": 0.435939,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.419246",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University",
      "url": "https://www.globenewswire.com/news-release/2025/12/09/3202446/0/en/Alpha-Tau-Successfully-Treats-First-Patient-in-its-U-S-Trial-for-Patients-with-Recurrent-Glioblastoma-at-the-James-Cancer-Hospital-at-The-Ohio-State-University.html",
      "time_published": "20251209T090000",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. has announced the successful treatment of the first patient in its U.S. pilot study for recurrent glioblastoma (GBM) using its Alpha DaRT\u00ae technology. This marks the first time Alpha DaRT has been used to treat brain cancer, addressing a critical unmet need for new therapies given GBM's aggressive nature and high recurrence rates. The study, conducted at The Ohio State University, evaluates the feasibility and safety of this novel alpha-radiation therapy for a highly challenging cancer.",
      "banner_image": "https://www.globenewswire.com/NewsRoom/AttachmentNg/71cc88b1-7458-45c0-8793-6d5c1cb1068f",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.949382"
        }
      ],
      "overall_sentiment_score": 0.432164,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.414012",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University",
      "url": "https://www.nasdaq.com/press-release/alpha-tau-successfully-treats-first-patient-its-us-trial-patients-recurrent",
      "time_published": "20251209T090000",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. has successfully treated the first patient in its U.S. pilot study for recurrent glioblastoma multiforme (GBM) using its Alpha DaRT technology at The Ohio State University. This marks the world's first Alpha DaRT treatment in the brain for this aggressive cancer, highlighting a significant step in addressing a critical unmet medical need. The study aims to evaluate the feasibility and safety of this novel alpha-radiation therapy, which has received FDA Breakthrough Device Designation.",
      "banner_image": "https://ml.globenewswire.com/Resource/Download/71cc88b1-7458-45c0-8793-6d5c1cb1068f/pr-pancreas-pr-impact-patient-1-v3.png",
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.925961"
        }
      ],
      "overall_sentiment_score": 0.85263,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.880498",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium",
      "url": "https://www.sahmcapital.com/news/content/alpha-tau-announces-presentation-of-two-alpha-dart-pancreatic-cancer-abstracts-at-upcoming-2026-asco-gi-symposium-2025-12-04",
      "time_published": "20251206T190930",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. announced that two abstracts detailing data from their Alpha DaRT pancreatic cancer pilot trial have been accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium. The abstracts will cover the feasibility, safety, and efficacy of endoscopic ultrasound-guided Alpha Radiotherapy, as well as inflammatory and immune marker dynamics following intratumoral Alpha DaRT for pancreatic cancer. This builds on previous presentations and highlights the company's progress in treating this difficult-to-manage cancer.",
      "banner_image": "NULL",
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.930022"
        }
      ],
      "overall_sentiment_score": 0.469627,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.490365",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Medical to Present Pancreatic Cancer Research at 2026 ASCO Symposium",
      "url": "https://www.tipranks.com/news/company-announcements/alpha-tau-medical-to-present-pancreatic-cancer-research-at-2026-asco-symposium",
      "time_published": "20251205T051150",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. announced that two abstracts related to its Alpha DaRT technology for pancreatic cancer have been accepted for presentation at the 2026 ASCO Gastrointestinal Cancers Symposium. The company's Alpha DaRT therapy is being investigated in a multi-center U.S. clinical study for this underserved patient population. Despite the positive clinical news, TipRanks\u2019 AI Analyst, Spark, rates DRTS as an \"Underperform\" due to financial challenges and lack of profitability.",
      "banner_image": "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_296599349-750x406.jpg",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.926242"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.831545"
        }
      ],
      "overall_sentiment_score": -0.228664,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.220873",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Alpha Tau announces two Alpha DaRT abstracts at ASCO Symposium",
      "url": "https://www.tipranks.com/news/the-fly/alpha-tau-announces-two-alpha-dart-abstracts-at-asco-symposium-thefly",
      "time_published": "20251205T051150",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical (DRTS) announced that two abstracts focusing on Alpha DaRT for advanced pancreatic cancer have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. The abstracts will cover the feasibility, safety, and efficacy of endoscopic ultrasound-guided Alpha Radiotherapy, as well as inflammatory and immune marker dynamics following intratumoral Alpha DaRT. This marks the second consecutive year Alpha Tau has presented pancreatic cancer study data at the ASCO symposium.",
      "banner_image": "NULL",
      "source": "TipRanks",
      "category_within_source": "General",
      "source_domain": "TipRanks",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.928051"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.645332"
        }
      ],
      "overall_sentiment_score": 0.427295,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.403660",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium",
      "url": "https://www.globenewswire.com/news-release/2025/12/04/3199857/0/en/Alpha-Tau-Announces-Presentation-of-Two-Alpha-DaRT-Pancreatic-Cancer-Abstracts-at-Upcoming-2026-ASCO-GI-Symposium.html",
      "time_published": "20251204T090000",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. has announced that two abstracts concerning Alpha DaRT for pancreatic cancer will be presented at the 2026 ASCO Gastrointestinal Cancers Symposium. The presentations will detail findings from the recently completed pancreatic cancer pilot trial in Montreal, Canada, as the company progresses with its U.S. multi-center clinical trial for pancreatic cancer. This highlights Alpha Tau's commitment to addressing the high unmet needs of pancreatic cancer patients.",
      "banner_image": "https://ml.globenewswire.com/media/ZjVhYTUxOWItNjFjOC00OGY0LWJiYzItYTAyMGM4MzQ5NTU0LTEyNjEwOTEtMjAyNS0xMi0wNC1lbg==/tiny/Alpha-Tau-Medical-Ltd-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.915710"
        }
      ],
      "overall_sentiment_score": 0.437604,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.442088",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium",
      "url": "https://finance.yahoo.com/news/alpha-tau-announces-presentation-two-140000100.html",
      "time_published": "20251204T071856",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) will present two abstracts on its Alpha DaRT pancreatic cancer therapy at the 2026 ASCO Gastrointestinal Cancers Symposium. These presentations will detail findings from a recently completed pilot trial in Montreal, Canada, showcasing the treatment's feasibility, safety, and efficacy, as well as inflammatory and immune marker dynamics. The company also announced that patient recruitment for its U.S. multi-center pancreatic cancer clinical trial, which began in September 2025, is expected to conclude by the end of Q1 2026.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2CfPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.477307,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.459622",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau (NASDAQ: DRTS) gains FDA IDE to test Alpha DaRT in recurrent prostate cancer",
      "url": "https://www.stocktitan.net/news/DRTS/alpha-tau-receives-fda-approval-to-initiate-a-trial-for-patients-ajqz0hqt74c6.html",
      "time_published": "20251203T051150",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. announced that the FDA approved an Investigational Device Exemption (IDE) to initiate a pilot study of its Alpha DaRT technology for patients with locally recurrent prostate cancer. This is Alpha Tau\u2019s fifth active U.S. IDE, and the study will enroll up to 12 patients to evaluate safety as its primary objective, with secondary objectives focusing on biochemical and clinical progression and overall survival. The company positions Alpha DaRT as a targeted local salvage alpha-radiation option, potentially replacing systemic androgen deprivation therapy for this patient group.",
      "banner_image": "https://ml.globenewswire.com/media/NzhhYjhlZDYtYzU4YS00ODQ3LThhNmQtYjA2ZmE0NTU3NDhjLTEyNjEwOTEtMjAyNS0xMi0wMi1lbg==/tiny/Alpha-Tau-Medical-Ltd-.png",
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.922629"
        },
        {
          "topic": "finance",
          "relevance_score": "0.628589"
        }
      ],
      "overall_sentiment_score": 0.020731,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "0.324815",
          "ticker_sentiment_score": "0.021734",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer",
      "url": "https://www.globenewswire.com/news-release/2025/12/02/3198023/0/en/Alpha-Tau-Receives-FDA-Approval-to-Initiate-a-Trial-for-Patients-with-Locally-Recurrent-Prostate-Cancer.html",
      "time_published": "20251202T201030",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. announced FDA approval for an Investigational Device Exemption (IDE) to begin a pilot study for locally recurrent prostate cancer using its Alpha DaRT technology. This marks Alpha Tau's fifth active U.S. IDE, expanding its reach into prostate cancer treatment with a new potential local salvage therapy. The study aims to evaluate the safety and efficacy of Alpha DaRT in up to 12 U.S. patients.",
      "banner_image": "https://ml.globenewswire.com/media/NzhhYjhlZDYtYzU4YS00ODQ3LThhNmQtYjA2ZmE0NTU3NDhjLTEyNjEwOTEtMjAyNS0xMi0wMi1lbg==/tiny/Alpha-Tau-Medical-Ltd-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        }
      ],
      "overall_sentiment_score": 0.40998,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.428079",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer",
      "url": "https://finance.yahoo.com/news/alpha-tau-receives-fda-approval-140000740.html",
      "time_published": "20251130T210947",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. announced that the FDA has approved an Investigational Device Exemption application for a pilot study investigating their Alpha DaRT technology for locally recurrent prostate cancer. The trial aims to enroll up to 12 U.S. patients to evaluate the safety and efficacy of Alpha DaRT as a local salvage therapy, offering a new option beyond systemic androgen deprivation therapy. This marks Alpha Tau's fifth active U.S. IDE, expanding their reach across various tumor types.",
      "banner_image": "https://s.yimg.com/ny/api/res/1.2/rj0Ta3GGeVAy26gXI.Thag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDtoPTQ4O2NmPXdlYnA-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/b2b7bbc0-8385-11f0-977e-d9d7d4cd04d2",
      "source": "Yahoo Finance",
      "category_within_source": "General",
      "source_domain": "Yahoo Finance",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904571"
        }
      ],
      "overall_sentiment_score": 0.400598,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.429949",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update",
      "url": "https://www.globenewswire.com/news-release/2025/11/20/3192378/0/en/Alpha-Tau-Announces-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html",
      "time_published": "20251120T160500",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. has reported its third-quarter 2025 financial results, highlighting accelerated momentum with increased patient treatments and a newly received radioactive material license for its New Hampshire facility, positioning the company for commercial readiness. The company announced several upcoming milestones, including the completion of patient recruitment for key clinical trials and the treatment of the first patient in its U.S. multi-center pancreatic cancer study. Alpha Tau concluded the quarter with a strong cash balance of $75.9 million, providing a runway for continued clinical advancement and commercial preparation, despite incurring a net loss of $30.5 million for the nine months ended September 30, 2025.",
      "banner_image": "https://ml.globenewswire.com/media/Y2I4ZDE2ZGUtMGE3Ni00ZWVlLWI0MzYtMzc5NWY4ZWI5YWE5LTEyNjEwOTEtMjAyNS0xMS0yMC1lbg==/tiny/Alpha-Tau-Medical-Ltd-.png",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.929010"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.824449"
        }
      ],
      "overall_sentiment_score": 0.484434,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.474610",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Bassett Cancer Institute Among First Cancer Centers in the Nation to Participate in Alpha DaRT\u00ae Pancreatic Cancer Clinical Trial",
      "url": "https://www.bassett.org/news/bassett-cancer-institute-among-first-cancer-centers-nation-participate-alpha-dartr-pancreatic",
      "time_published": "20251117T051150",
      "authors": [
        "NULL"
      ],
      "summary": "The Bassett Cancer Institute is participating in an international clinical trial for patients with inoperable, advanced, or metastatic pancreatic cancer, utilizing Alpha Tau Medical Ltd.\u2019s Alpha DaRT\u00ae radiation therapy. This makes it one of the first centers in the U.S. to offer this innovative treatment, which involves implanting radioactive alpha particle sources directly into the tumor. The trial aims to study new treatments for pancreatic cancer, a difficult-to-treat disease, benefiting both patients and the medical community.",
      "banner_image": "NULL",
      "source": "Bassett Healthcare Network",
      "category_within_source": "General",
      "source_domain": "Bassett Healthcare Network",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.926482"
        }
      ],
      "overall_sentiment_score": 0.479641,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.470015",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Medical (NASDAQ:DRTS) Upgraded at Wall Street Zen",
      "url": "https://www.marketbeat.com/instant-alerts/alpha-tau-medical-nasdaqdrts-upgraded-at-wall-street-zen-2025-11-01/",
      "time_published": "20251102T055218",
      "authors": [
        "MarketBeat"
      ],
      "summary": "Alpha Tau Medical (NASDAQ:DRTS) was upgraded to a \"sell\" rating by Wall Street Zen, contrasting with HC Wainwright's reiterated \"buy\" rating and $9.00 target price. The company's stock experienced recent fluctuations, trading at $4.16 with a market cap of $352.85 million. Institutional investor XTX Topco Ltd recently acquired 21,195 shares, contributing to the 2.65% institutional ownership.",
      "banner_image": null,
      "source": "MarketBeat",
      "category_within_source": "General",
      "source_domain": "MarketBeat",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.904088"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.838357"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.706598"
        }
      ],
      "overall_sentiment_score": -0.209948,
      "overall_sentiment_label": "Somewhat-Bearish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "-0.192061",
          "ticker_sentiment_label": "Somewhat-Bearish"
        }
      ]
    },
    {
      "title": "Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness",
      "url": "https://www.sahmcapital.com/news/content/alpha-tau-announces-receipt-of-radioactive-material-license-for-its-new-hampshire-manufacturing-facility-advancing-towards-commercial-readiness-2025-10-21",
      "time_published": "20251021T153000",
      "authors": [],
      "summary": "Alpha Tau Medical Ltd. has secured a radioactive material license for its new commercial-scale manufacturing facility in Hudson, New Hampshire, a critical step towards commercial readiness. This license enables the introduction of radioactive material, paving the way for Alpha DaRT treatment manufacturing to begin in 2026. The facility's first phase is expected to produce approximately 400,000 Alpha DaRT sources.",
      "banner_image": null,
      "source": "Sahm",
      "category_within_source": "General",
      "source_domain": "Sahm",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.902403"
        },
        {
          "topic": "manufacturing",
          "relevance_score": "0.738566"
        }
      ],
      "overall_sentiment_score": 0.46622,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.453385",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Medical: Localized Alpha Radiation, A New Paradigm In Oncology (NASDAQ:DRTS) - Seeking Alpha",
      "url": "https://seekingalpha.com/article/4830482-alpha-tau-medical-localized-alpha-radiation-a-new-paradigm-in-oncology",
      "time_published": "20251016T155545",
      "authors": [
        "Anders Research"
      ],
      "summary": "Alpha Tau Medical is developing Alpha DaRT, a unique localized alpha radiation therapy showing potential best-in-class efficacy for various solid tumors. The company is currently enrolling patients in multiple clinical trials and has several upcoming milestones. Despite promising data and broad potential, Alpha Tau's current market capitalization of ~$330 million is considered significantly undervalued.",
      "banner_image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2151333984/image_2151333984.jpg?io=getty-c-w750",
      "source": "Seeking Alpha",
      "category_within_source": "General",
      "source_domain": "Seeking Alpha",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "1.000000"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.613252"
        },
        {
          "topic": "finance",
          "relevance_score": "0.407182"
        }
      ],
      "overall_sentiment_score": 0.02776,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "0.338606",
          "ticker_sentiment_score": "0.029329",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "Alpha Tau Successfully Treats First Patient in Pancreatic Cancer Clinical Trial",
      "url": "https://www.itnonline.com/content/alpha-tau-successfully-treats-first-patient-pancreatic-cancer-clinical-trial",
      "time_published": "20250905T000000",
      "authors": [],
      "summary": "Alpha Tau Medical Ltd. has successfully treated the first patient in its U.S. multi-center pancreatic cancer pilot study, IMPACT, which evaluates Alpha DaRT in combination with chemotherapy for newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma. Pancreatic cancer is a leading cause of cancer-related death, and this trial aims to explore a novel treatment approach using localized alpha radiation for patients with limited options. The treatment involves precisely delivering Alpha DaRT sources into pancreatic tumors under real-time endoscopic ultrasound guidance, a minimally invasive method that offers the potential for high local control and systemic response.",
      "banner_image": null,
      "source": "Imaging Technology News",
      "category_within_source": "General",
      "source_domain": "Imaging Technology News",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.916486"
        }
      ],
      "overall_sentiment_score": 0.839908,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.840283",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update",
      "url": "https://www.globenewswire.com/news-release/2025/08/11/3131225/0/en/Alpha-Tau-Announces-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html",
      "time_published": "20250811T160200",
      "authors": [
        "NULL"
      ],
      "summary": "Alpha Tau Medical Ltd. reported its Q2 2025 financial results, highlighting significant progress in its U.S. clinical trials for Alpha DaRT\u00ae, including FDA approval for a GBM pilot study and imminent patient treatment initiation for pancreatic cancer. The company secured $36.9 million in equity funding and reported a cash balance of $83.3 million to support continued clinical advancement and commercial preparations. Additionally, Alpha Tau updated on its manufacturing facility construction and expected regulatory responses.",
      "banner_image": "NULL",
      "source": "GlobeNewswire",
      "category_within_source": "General",
      "source_domain": "GlobeNewswire",
      "topics": [
        {
          "topic": "earnings",
          "relevance_score": "0.911420"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.814405"
        },
        {
          "topic": "finance",
          "relevance_score": "0.621981"
        }
      ],
      "overall_sentiment_score": 0.418664,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.401671",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Medical Ltd. Reports Promising Interim Results for Alpha DaRT\u00ae in Pancreatic Cancer Trials and Achieves Key Regulatory Milestones",
      "url": "https://www.nasdaq.com/articles/alpha-tau-medical-ltd-reports-promising-interim-results-alpha-dartr-pancreatic-cancer",
      "time_published": "20250519T161300",
      "authors": [
        "None for Quiver Quantitative"
      ],
      "summary": "Alpha Tau Medical announced promising interim results for its Alpha DaRT\u00ae therapy in pancreatic cancer trials, showing over 90% disease control rates and strong overall survival. The company also achieved key regulatory milestones, including FDA approvals for new U.S. pilot studies in pancreatic cancer and glioblastoma, and MDSAP certification for its Jerusalem facility. Despite an increase in net loss, a recent $36.9 million financing bolsters its capital position to support ongoing clinical and commercialization efforts.",
      "banner_image": null,
      "source": "Nasdaq",
      "category_within_source": "General",
      "source_domain": "Nasdaq",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.923262"
        },
        {
          "topic": "earnings",
          "relevance_score": "0.811602"
        }
      ],
      "overall_sentiment_score": 0.503219,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.517770",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Watkins Advises Alpha Tau Medical in US$36.9 Million Registered Direct Offering",
      "url": "https://www.lw.com/en/news/2025/04/latham-watkins-advises-alpha-tau-medical-in-us36-9-million-registered-direct-offering",
      "time_published": "20250430T000000",
      "authors": [],
      "summary": "Latham & Watkins advised Alpha Tau Medical Ltd. on a registered direct offering of 14,110,121 ordinary shares to an affiliate of Oramed Pharmaceuticals Inc. for US$2.612 per share. The offering, which closed on April 28, 2025, generated approximately US$36.9 million in gross proceeds for Alpha Tau. The Latham team included partners and associates from London, Tel Aviv, and Century City.",
      "banner_image": null,
      "source": "Latham & Watkins LLP",
      "category_within_source": "General",
      "source_domain": "Latham & Watkins LLP",
      "topics": [
        {
          "topic": "finance",
          "relevance_score": "0.901008"
        },
        {
          "topic": "life_sciences",
          "relevance_score": "0.802511"
        }
      ],
      "overall_sentiment_score": 0.602675,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.628181",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "FDA Approves IDE Application for Alpha DaRT in Recurrent Glioblastoma",
      "url": "https://www.targetedonc.com/view/fda-approves-ide-application-for-alpha-dart-in-recurrent-glioblastoma",
      "time_published": "20250403T000000",
      "authors": [
        "Jordyn Sava"
      ],
      "summary": "The FDA has approved an Investigational Device Exemption (IDE) application for a pilot study evaluating Alpha DaRT technology in patients with recurrent glioblastoma (GBM). This technology uses radium-224 impregnated sources for localized alpha-irradiation of solid tumors, aiming to minimize exposure to healthy tissues. The study will assess the safety and feasibility of Alpha DaRT in up to 10 patients with recurrent GBM not treatable by surgery, building on prior recognitions like Breakthrough Device Designation and promising preclinical and preliminary clinical trial results in other cancers.",
      "banner_image": null,
      "source": "Targeted Oncology",
      "category_within_source": "General",
      "source_domain": "Targeted Oncology",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.913697"
        }
      ],
      "overall_sentiment_score": 0.005071,
      "overall_sentiment_label": "Neutral",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "0.321041",
          "ticker_sentiment_score": "0.000065",
          "ticker_sentiment_label": "Neutral"
        }
      ]
    },
    {
      "title": "H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock at $9 target",
      "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-alpha-tau-medical-stock-at-9-target-93CH-4221487",
      "time_published": "20250309T074300",
      "authors": [
        "Investing.com"
      ],
      "summary": "H.C. Wainwright has reiterated its Buy rating and $9.00 price target for Alpha Tau Medical Ltd. following the initiation of its U.S. pilot study for pancreatic cancer treatment, Alpha DaRT. The company's stock has seen significant growth in the past year, and analyst targets suggest further upside potential, supported by a strong financial position.",
      "banner_image": null,
      "source": "Investing.com",
      "category_within_source": "General",
      "source_domain": "Investing.com",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.802610"
        },
        {
          "topic": "financial_markets",
          "relevance_score": "0.727629"
        }
      ],
      "overall_sentiment_score": 0.437535,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.427877",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    },
    {
      "title": "Alpha Tau Treats First Patient with Advanced Inoperable Pancreatic Cancer at Israel\u2019s Hadassah Medical Center",
      "url": "https://www.stocktitan.net/news/DRTS/alpha-tau-treats-first-patient-with-advanced-inoperable-pancreatic-wcj7g0vepy0d.html",
      "time_published": "20230914T083000",
      "authors": [],
      "summary": "Alpha Tau Medical Ltd. announced it has treated the first patient with advanced inoperable pancreatic cancer in a clinical trial at Hadassah Medical Center in Jerusalem, Israel, using its Alpha DaRT\u2122 therapy. This trial aims to offer a new treatment option for patients with solid tumors who lack other therapeutic alternatives. The company highlights the potential of Alpha DaRT to transform cancer treatment, especially for aggressive diseases like pancreatic cancer, which has a very low survival rate.",
      "banner_image": null,
      "source": "Stock Titan",
      "category_within_source": "General",
      "source_domain": "Stock Titan",
      "topics": [
        {
          "topic": "life_sciences",
          "relevance_score": "0.936731"
        }
      ],
      "overall_sentiment_score": 0.402085,
      "overall_sentiment_label": "Bullish",
      "ticker_sentiment": [
        {
          "ticker": "DRTS",
          "relevance_score": "1.000000",
          "ticker_sentiment_score": "0.437791",
          "ticker_sentiment_label": "Bullish"
        }
      ]
    }
  ]
}